Fusion Antibodies News
Fusion Antibodies and Bizcom Japan continue to strengthen ties.
Fusion Antibodies and BizCom Japan, a privately-held Japan-based trading and consulting company, continue to strengthen ties with Fusion’s Director Paul Kerr attending BioJapan 2016 with BizCom Japan’s Director Hiroyasu Nakatani.
BizCom…
Fusion Antibodies announces Cell Line Development collaboration with Celonic
Fusion Antibodies are happy to announce we have entered into a partnership with Swiss contract manufacturing organisation Celonic AG to collaborate on the development of high yield stable cell lines.
The deal will allow clients…
Fusion Antibodies announces collaboration with Aerpio Therapeutics for second Antibody Humanization project
Fusion Antibodies are pleased to announce a second collaboration with Aerpio Therapeutics to apply our CDRx Antibody Humanization platform to Aerpio’s Mouse Monoclonal Antibody.
Fusion Antibodies Ltd are excited to announce our second…
Why is Antibody Humanization still important in the 21st century?
Monoclonal antibodies, or mAbs, have become a crucial tool and are used for both diagnostic and medical applications. This article will explain the importance of mAbs and antibody humanization techniques involved.
If you…
